Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Merck shares early PD-1xVEGF bispecific data in NSCLC but withholds phase 3 plans, raising questions about GMP scale-up readiness.
Pharma Now Editorial Team

Oral biologics and macrocycle drugs are driving new formulation and manufacturing demands that pharma plants must prepare for now.
Pharma Now Editorial Team

ARS Pharma's nasal epinephrine approval highlights GMP, process validation, and regulatory challenges facing manufacturers pursuing delivery reformulations.
Pharma Now Editorial Team

Xilio's preclinical data for masked T cell engager XTX601 show tumor-selective activation and NHP tolerability, with an IND filing planned for 2027.
Pharma Now Editorial Team
